HQH: Efficient Fund To Collect Income From Healthcare

abrdn Healthcare Investors (HQH), a closed-end fund with a 13.6% dividend yield, offers an attractive income stream and exposure to the growing healthcare sector, particularly biotechnology, pharmaceuticals, and healthcare equipment which make up 85% of its holdings. While HQH has underperformed some of its holdings due to its income focus, it has historically outperformed traditional healthcare ETFs and is positioned to benefit from increased healthcare spending driven by factors like rising drug costs and greater health consciousness; however, potential margin pressure from pricing transparency regulations could pose a challenge for some large-cap healthcare companies within the fund.

Analysis

Abrdn Healthcare Investors (HQH), a closed-end fund, presents an income-focused investment proposition with a current dividend yield of 13.6%. Despite an 8.5% price decline over the past year, dividends contributed to a 3.9% total return. The fund, established in 1987 with a 0.97% management fee, currently trades at an 8% discount to Net Asset Value (NAV), which is wider than the peer average of 5.5%, although HQH has historically traded at discounts exceeding 10% since 2020. With $951 million in net assets distributed across approximately 140 holdings, HQH maintains a significant concentration in biotechnology (65.4%), followed by pharmaceuticals (10.9%) and healthcare equipment (8.6%). Noteworthy holdings include Gilead (GILD), Amgen (AMGN), and Eli Lilly (LLY). The fund is positioned to benefit from projected increases in commercial healthcare spending, expected to reach a 13-year high driven by drug costs, inflation, and growth in areas like behavioral health, which is estimated to become a $166 billion market by 2033. However, President Trump's executive order on healthcare pricing transparency introduces regulatory uncertainty, potentially pressuring margins for insurers like UnitedHealth Group (UNH) and Cigna (CI), though it may also foster opportunities for companies adopting transparent pricing. HQH's 2024 earnings of $3.53 per share adequately covered its $2.16 annual distribution; however, distributions have historically varied and can include return of capital, making the fund potentially more suitable for tax-advantaged accounts.

Key Decisions for Investors

• Investors seeking high current income and diversified exposure to the healthcare sector, particularly biotechnology, may find HQH's 13.6% yield and historical outperformance of benchmarks like XLV appealing.
• Careful consideration should be given to HQH's trading discount to NAV, which at 8% is wider than peers but has historically been larger, presenting both a potential value opportunity and a risk of further discount widening.
• Due to the nature of its distributions, which can comprise net investment income, realized gains, and return of capital, holding HQH within a tax-advantaged account could be beneficial to optimize after-tax returns.
• Monitor the evolving impact of healthcare pricing transparency regulations on the fund's underlying holdings, especially large-cap pharmaceutical and insurance companies, as this could influence future profitability and investor sentiment within the sector.